Bioactive factors-imprinted scaffold vehicles for boosting bone repair

NewsGuard 100/100 Score

Announcing a new article publication for BIO Integration journal. In this review article the authors Peng-Peng Xue, Jian-dong Yuan, Qing Yao, Ying-Zheng Zhao and He-Lin Xu, from Wenzhou Medical University, Wenzhou City, China consider bioactive factors-imprinted scaffold vehicles for promoting bone healing.

Wound repair of bone is a complicated multistep process orchestrated by inflammation, angiogenesis, callus formation, and bone remodeling. Many bioactive factors (BFs) including cytokine and growth factors (GFs) have previously been reported to be involved in regulating wound healing of bone and some exogenous BFs such as bone morphogenetic proteins (BMPs) were proven to be helpful for improving bone healing. In this regard, the BFs reported for boosting bone repair were initially categorized according to their regulatory mechanisms.

In this review article the authors outline the challenges, including short half-life, poor stability, and rapid enzyme degradation and deactivation, for these exogenous BFs in bone healing. For these issues, BFs-imprinted scaffold vehicles have recently been reported to promote the stability of BFs and enhance their half-life in vivo.

The authors focus on the incorporation of BFs into the modulated biomaterials with various forms of bone tissue engineering applications: firstly, rigid bone graft substitutes (BGSs) were used to imprint BFs for large scale bone defect repair; secondly, the soft sponge-like scaffold carrying BFs are discussed as filling materials for the cavity of bone defects; thirdly, various injectable vehicles including hydrogel, nanoparticles, and microspheres for the delivery of BFs were also introduced for irregular bone fracture repair. Challenges for BFs-imprinted scaffold vehicles are also analyzed.

Source:
Journal reference:

Peng-Peng, X., et al. (2020) Bioactive Factors-imprinted Scaffold Vehicles for Promoting Bone Healing: The Potential Strategies and the Confronted Challenges for Clinical Production. BIO Integration. doi.org/10.15212/bioi-2020-0010.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Advancing osteosarcoma prognosis with AI-assisted tumor cell density analysis